Publication Name	World Journal of Gastroenterology
Manuscript ID	123681
Country	China

Category	Cell & Tissue Engineering
Manuscript Type	Review
Article Title	Small extracellular vesicles as liquid biopsy targets and precision therapeutics for metabolic dysfunction-associated steatotic liver disease
Manuscript Source	Unsolicited Manuscript
All Author List	Ling-Ling Ding, Han Liu, Yang Yu, Xue-Chao Liu, Shu-Qin Zhang, Hui Qian and Dong-Lin Hao
Funding Agency and Grant Number	Funding Agency Grant Number the High-Level Talent Scientific Research Start-up Funding of Jiangsu University 5501280008 Jiangsu Province Double Innovation Doctoral Talent Program JSSCBS20221179 the China Postdoctoral Science Foundation 2023M741425 the Industry-University-Research Cooperation Project with Nanjing EVLiXiR 8411283025
Corresponding Author	Ling-Ling Ding, Wujin Institute of Molecular Diagnostics and Precision Cancer Medicine of Jiangsu University, Wujin Hospital Affiliated with Jiangsu University, No. 2 Yongning North Road, Changzhou 213002, Jiangsu Province, China. l.ding@ujs.edu.cn
Key Words	Metabolic dysfunction-associated steatotic liver disease; Small extracellular vesicles; Extracellular vesicles; Liquid biopsy; Biomarkers; Noninvasive tests; Drug delivery systems; Therapeutic strategies
Core Tip	Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks non-invasive biomarkers and targeted therapies. Small extracellular vesicles (sEVs) offer dual solutions: As diagnostic tools, sEV-derived miRNAs (e.g., miR-122), proteins (e.g., Kelch-like protein 41), and lipids enable accurate staging; as therapeutics, mesenchymal stem cell-derived sEVs reduce steatosis and fibrosis via autophagy and oxidative stress regulation, while engineered sEVs (e.g., cyclic arginine-glycine-aspartic acid-modified) enhance targeted delivery. sEVs thus shift from bystanders to key diagnostic and therapeutic players in MASLD.
Citation	Ding LL, Liu H, Yu Y, Liu XC, Zhang SQ, Qian H, Hao DL. Small extracellular vesicles as liquid biopsy targets and precision therapeutics for metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2026; In press

Received	2026-05-26 06:05
Peer-Review Started	2026-05-26 06:06
First Decision by Editorial Office Director
Return for Revision	2026-07-31 02:06
Revised	2026-08-13 12:46
Publication Fee Transferred	2026-09-08 02:46
Second Decision by Editor	2026-10-08 07:09
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-10-08 09:04
Articles in Press	2026-10-08 09:04
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com